ZERBAXA - May 2026 pediatric renal regimens
- Product / population
- Pediatric ZERBAXA age 2 to below 18 with renal impairment; May 2026 label, Table 4. Doses are total ceftolozane+tazobactam.
- Renal measure
- Validated pediatric eGFR, mL/min/1.73 m2; not adult Cockcroft-Gault.
Renal dosing, restrictions and evidence limits
Age 2 to below 18 years: use a validated pediatric eGFR equation (mL/min/1.73 m2). For cIAI/cUTI, total combination mg/kg every eight hours at eGFR 51 to below 90, 30-50 and 15-29 are respectively 30, 15 and 7.5; infuse over one hour. For HABP/VABP, corresponding doses are 75, 37.5 and 18.75 mg/kg every eight hours over two hours. Intermittent HD: cIAI/cUTI loads 15 mg/kg then 3 mg/kg every eight hours; pneumonia loads 45 mg/kg then 9 mg/kg every eight hours. Give post-HD doses as early as possible after dialysis. Above 50 kg for cIAI/cUTI or 40 kg for pneumonia, do not exceed the adult renal dose. Below eGFR 15 without HD, dosing is not established. Renal-impairment dosing is not recommended below age two. Reassess changing eGFR daily. cIAI also requires metronidazole. These 2026 regimens supersede the older mirror's broad pediatric renal evidence gap.
Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70ac1d90-eff3-4f0b-9f46-5846c571b32f